Literature DB >> 26629867

Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.

Suzanne van Meer1, Karel J van Erpecum, Dave Sprengers, Minneke J Coenraad, Heinz-Josef Klümpen, Peter L M Jansen, Jan N M IJzermans, Joanne Verheij, Carin M J van Nieuwkerk, Peter D Siersema, Robert A de Man.   

Abstract

OBJECTIVES: Hepatocellular carcinoma (HCC) usually occurs in patients with cirrhosis, but can also develop in noncirrhotic livers. In the present study we explored associated risk factors for HCC without cirrhosis and compared patient and tumor characteristics and outcomes in HCC patients with and without underlying cirrhosis.
METHODS: Patients with HCC diagnosed in the period 2005-2012 in five Dutch academic centers were evaluated. Patients were categorized according to the presence of cirrhosis on the basis of histology or combined radiological and laboratory features.
RESULTS: In total, 19% of the 1221 HCC patients had no underlying cirrhosis. Noncirrhotic HCC patients were more likely to be female and to have nonalcoholic fatty liver disease or no risk factors for underlying liver disease, and less likely to have hepatitis C virus or alcohol-related liver disease than did cirrhotic HCC patients. HCCs in noncirrhotic livers were more often unifocal (67 vs. 48%), but tumor size was significantly larger (8 vs. 4 cm). Despite the larger tumors, more patients underwent resection (50 vs. 10%) and overall survival was significantly better than in cirrhotics. In multivariate analyses, absence of cirrhosis [hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.38-0.63] and presence of hepatitis B (HR 0.68, 95% CI 0.51-0.91) were independent predictors for lower mortality, whereas hepatitis C virus was associated with higher mortality (HR 1.32, 95% CI 1.01-1.65).
CONCLUSION: HCC without cirrhosis was strongly associated with female sex and presence of nonalcoholic fatty liver disease or no risk factors for underlying liver disease. In absence of cirrhosis, resections were more often performed, with better survival despite larger tumor size.

Entities:  

Mesh:

Year:  2016        PMID: 26629867     DOI: 10.1097/MEG.0000000000000527

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  15 in total

1.  Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas.

Authors:  Mehmet Sayiner; Zobair M Younossi
Journal:  Hepat Oncol       Date:  2016-03-23

2.  Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis.

Authors:  Lara Dakhoul; Keaton R Jones; Samer Gawrieh; Marwan Ghabril; Chelsey McShane; Raj Vuppalanchi; Eduardo Vilar-Gomez; Lauren Nephew; Naga Chalasani; Craig Lammert
Journal:  Dig Dis Sci       Date:  2019-01-07       Impact factor: 3.199

3.  Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry.

Authors:  Hans-Christian Pommergaard; Andreas Arendtsen Rostved; René Adam; Allan Rasmussen; Mauro Salizzoni; Miguel Angel Gómez Bravo; Daniel Cherqui; Paolo De Simone; Pauline Houssel-Debry; Vincenzo Mazzaferro; Olivier Soubrane; Juan Carlos García-Valdecasas; Joan Fabregat Prous; Antonio D Pinna; John O'Grady; Vincent Karam; Christophe Duvoux; Lau Caspar Thygesen
Journal:  Liver Cancer       Date:  2020-05-12       Impact factor: 11.740

4.  Hepatocellular carcinoma in patients with no identifiable risk factors.

Authors:  Caitlin A McIntyre; Joanne F Chou; Mithat Gonen; Jinru Shia; Maya Gambarin-Gelwan; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Jeffrey A Drebin; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2020-06-24       Impact factor: 3.647

5.  Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study.

Authors:  Coşkun Özer Demirtaş; Tuğba Tolu; Çaglayan Keklikkıran; Osman Cavit Özdoğan; Feyza Gündüz
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

Review 6.  Controversies and evidence of hepatic resection for hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Guido Torzilli; Hao Xing; Chao Li; Jun Han; Lei Liang; Han Zhang; Shu-Yang Dai; Le-Qun Li; Feng Shen; Tian Yang
Journal:  BBA Clin       Date:  2016-10-11

7.  Operable synchronous ampullary carcinoma and hepatocellular carcinoma: a case report and review of the literature.

Authors:  Marson Davidson; Miriam Aioub; Martin Gutierrez; Kunchang Song; Ellen Hagopian; Martin Karpeh
Journal:  J Surg Case Rep       Date:  2017-09-21

8.  Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing country.

Authors:  Danijel Galun; Aleksandar Bogdanovic; Jelena Djokic Kovac; Predrag Bulajic; Zlatibor Loncar; Marinko Zuvela
Journal:  Cancer Manag Res       Date:  2018-05-04       Impact factor: 3.989

9.  Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Chien-Wei Su; Yi-Jhen He; Yun-Hsuan Lee; Yi-Hsiang Huang; Ming-Chih Hou; Teh-Ia Huo
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

10.  Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting.

Authors:  Musomba Rachel; Castelnuovo Barbara; Claire Murphy; Charlene Komujuni; Patience Nyakato; Ponsiano Ocama; Mohammed Lamorde; Philippa Easterbrook; Rosalind Parkes Ratanshi
Journal:  Hepatol Med Policy       Date:  2018-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.